Market news

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

The biotech is developing innovative therapies for people with eye diseases.

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51.

Kodiak Sciences Inc. (NASDAQ:KOD) saw its share price nearly triple on Monday to a near five-year high, as investors loaded positions to cheer strong clinical trial results for its wet AMD treatment candidate. In intraday trading, the stock soared by as much as 196 percent before trimming gains to finish the session just up by […]

Kodiak Sciences Inc. stock jumps 140% on Phase 3 DAYBREAK wet AMD results. Click for this updated look at KOD and see if it belongs in your portfolio.

Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved

Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement. Both experimental drugs demonstrated...

Here are some of the companies making headlines in midday trading.

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.

Key TakeawaysKodiak Sciences shares jumped about 141% after its drug Zenkuda met its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD. Zenkuda’s edge is durability: it matched aflibercept on vision gains while 54% of its patients were on 6-month dosing under strict retreatment rules.

Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.

Nvidia launches the largest-ever U.S. stock buyback.

Kodiak Sciences shares saw their biggest ever single-day gains after the company posted positive Phase 3 data for 2 therapies targeting wet age-related macular degeneration.

Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.

Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved

Kodiak Sciences (NASDAQ:KOD) shares rose 31. 9% in pre-market trading after the company released topline results from its DAYBREAK pivotal Phase 3 study evaluating two investigational therapies in patients with wet age-related macular degeneration.

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026.

Kodiak Sciences (KOD) upcoming phase III wet AMD data could provide upside following the stock's rec

Kodiak Sciences recently highlighted that it is on track to report top-line Phase III DAYBREAK results for Zenkuda (tarcocimab tedromer) and KSI-501 in treatment-naïve wet age-related macular degeneration, part of a broader push into retinal vascular diseases that it views as a roughly US$15.00 billion anti-VEGF market. The company’s additional late-stage programs, including the PEAK and PINNACLE trials in macular edema and the ALTO study of KSI-501 in diabetic macular edema, position its...

Kodiak Sciences has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$31.52 level is supported by the company’s book value. With that kind of price action, the key issue for you is how much of Kodiak Sciences’ balance sheet strength is already reflected in today’s valuation. Over the past 3 years the stock has delivered a very large gain of about 15x. As a result, any discussion of value now needs to start with how much balance sheet support...

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

Kodiak expects Phase 3 DAYBREAK results for Zenkuda and KSI-501 this month in wet AMD. Read why KOD stock is a hold.

Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.